Expand ADTX Menu
ADTX MENU

ADTX Latest Press Releases

-- January 13, 2025 --

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform Business Wire 8:15 AM

-- December 12, 2024 --

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials Business Wire 8:15 AM

-- November 19, 2024 --

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. Globe Newswire 7:17 AM

-- November 14, 2024 --

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 PRNewswire 4:36 PM
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 Globe Newswire 7:15 AM

-- November 8, 2024 --

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares Business Wire 8:30 AM

-- November 7, 2024 --

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders Business Wire 8:30 AM

-- November 6, 2024 --

Appili Therapeutics Announces Results of Special Meeting of Shareholders Globe Newswire 5:55 PM
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem Business Wire 8:30 AM
Evofem Secures Investor Support for Proposed Merger through Voting Agreements PRNewswire 8:00 AM

-- October 31, 2024 --

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission Business Wire 8:30 AM
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission Globe Newswire 7:16 AM

-- October 30, 2024 --

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time Business Wire 5:00 PM

-- October 29, 2024 --

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives Business Wire 8:15 AM

-- October 28, 2024 --

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem Business Wire 8:15 AM

-- October 21, 2024 --

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time Business Wire 8:15 AM

-- October 10, 2024 --

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval Business Wire 8:15 AM

-- October 9, 2024 --

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time Business Wire 10:52 AM

-- October 8, 2024 --

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem Business Wire 8:15 AM

-- October 3, 2024 --

Aditxt Delivers Shareholder Update and 2024 Year-End Plan Business Wire 8:15 AM

-- September 27, 2024 --

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024 Business Wire 8:15 AM

-- September 24, 2024 --

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt Business Wire 8:15 AM

-- September 20, 2024 --

Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 Business Wire 8:15 AM

-- September 9, 2024 --

Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024 Business Wire 8:15 AM

-- September 4, 2024 --

Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic Prostate Test, Targeting Early Detection in High-Risk Patients Business Wire 8:15 AM

-- August 29, 2024 --

Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024 Business Wire 8:15 AM

-- August 26, 2024 --

Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic Endometriosis Test (MET ) and Mitomic Prostate Test (MPT ) Business Wire 8:15 AM

-- August 21, 2024 --

Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics Business Wire 8:15 AM

-- August 20, 2024 --

Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution PRNewswire 8:17 AM